Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cognaisent
AddedFeb 18, 2024
UpdatedJun 18, 2026
Cognaisent

Cognaisent

Cognaisent: Revolutionizing AI with machine learning for drug discovery and molecular analysis.

HQ
Cambridge, MA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize artificial intelligence, Cognaisent specializes in machine learning, deep learning, drug discovery, and molecular analysis. The company aims to leverage advanced AI technologies to make significant strides in these fields, ultimately contributing to a better world. Their core offerings include AI-driven solutions for drug discovery and molecular analysis, targeting both the healthcare and pharmaceutical markets.

Notable figures affiliated with Cognaisent include leading experts in AI and biotechnology. The company has attracted investment from prominent venture capital firms specializing in technology and healthcare innovations. Key achievements include breakthroughs in AI algorithms that have accelerated drug discovery processes and enhanced molecular analysis accuracy. Cognaisent's impact is marked by its contributions to both technological advancements and potential healthcare improvements.

Cognaisent - Similar Companies

DeepCure logo

DeepCure

deepcure.ai

Numerion Labs logo

Numerion Labs

numerionlabs.ai

Cognida.ai logo

Cognida.ai

cognida.ai

CognitiveCare logo

CognitiveCare

cognitivecare.com

Insitro logo

Insitro

insitro.com

Cogitativo logo

Cogitativo

cogitativo.com

AI Nexus logo

AI Nexus

Atomic AI logo

Atomic AI

atomic.ai

Cognaize logo

Cognaize

cognaize.com

Cognum logo

Cognum

cognum.ai

NumberOne AI logo

NumberOne AI

numberone.ai

MindBuilder AI logo

MindBuilder AI

mindbuilderai.com

OccamzRazor logo

OccamzRazor

occamzrazor.com

Phronesis Artificial Intelligence logo

Phronesis Artificial Intelligence

phronesisai.com

Cognizer logo

Cognizer

cognizer.ai

Cognaisent - Quick Facts

Who are Cognaisent's competitors?

Companies similar to Cognaisent include DeepCure, Numerion Labs, Cognida.ai and CognitiveCare.

When was Cognaisent founded?

Cognaisent was founded in 2018.

Where is Cognaisent's headquarters located?

Cognaisent's headquarters is located in Cambridge, MA, US.

When was Cognaisent's last funding round?

Cognaisent's most recent funding round was for $24k (USD) in January 2019.

How much has Cognaisent raised to-date?

As of Jan 1, 2019, Cognaisent has raised a total of $147k (USD).

How many employees does Cognaisent have?

Cognaisent has 7 employees as of Feb 5, 2024.

Cognaisent - Classification

Ownership
  • Venture Capital
Technology
  • AI
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • AI Operations
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software